Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.77 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.77 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | MTOR | P42345 | 1/20 | 0.63 |
| ▸ | PRKDC | P78527 | 1/20 | 0.63 |
| ▸ | PIK3C2B | O00750 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894826 | 0.93 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL21029086 | 0.91 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL12895066 | 0.91 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL12921164 | 0.90 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL1259614 | 0.89 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL12895139 | 0.89 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL12895133 | 0.89 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL7915730 | 0.87 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL15889210 | 0.86 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL12895144 | 0.86 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20220372048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2022-11-24 | — | — | US | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3613743-A1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | Intellikine, LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613743-A1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | Intellikine, LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-2240452-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES AS PI3 KINASE MODULATORS, THEIR COMPOSITIONS AND USES | INTELLIKINE LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20140206684-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206684-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8703777-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703777-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703777-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2240452-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Intellikine, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009088990-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | PIK3CD 3/4885PIK3CG 2/4885PIK3CA 1/4885 |
| US-20140206684-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CD 7/4885PIK3CG 8/4885PIK3CA 1/4885 |
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PTEN, PIK3C2A, PIK3CA | PIK3CD 5/4885PIK3CG 8/4885PIK3CA 3/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CD 6/4885PIK3CG 15/4885PIK3CA 1/4885 |
| US-20220372048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CD 7/4885PIK3CG 8/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.